Navigation Links
BioLife Solutions and STEMCELL Technologies Announce Worldwide Distribution Agreement
Date:8/17/2009

BOTHELL, Wash., Aug. 17 /PRNewswire-FirstCall/ -- BioLife Solutions, Inc. (OTC Bulletin Board: BLFS), a leading manufacturer and marketer of biopreservation tools for cells, tissues, and organs, today announced that it has entered into a non-exclusive distribution agreement with STEMCELL Technologies, Inc., based in Vancouver, Canada. STEMCELL Technologies, a member of the StemCell Group of companies, is a leading provider of products that support innovative research in hematology, immunology, cancer research, developmental biology, and many other areas of life science research.

Mike Rice, BioLife's chairman and CEO, noted, "We're very pleased to now have our products represented and distributed throughout the world by STEMCELL Technologies and their sub-distributor partners. Their MethoCult(R) reagent systems have become worldwide standards and we look forward to their distribution network's ability to help our HypoThermosol and CryoStor product platforms achieve the same level of product adoption."

Allen Eaves M.D., Ph.D., founder of STEMCELL Technologies and Chairman of the StemCell Group, commented on the addition of BioLife's products to their reagents and media portfolio by stating, "Our interest in BioLife Solutions has grown as we've seen their products adopted by numerous customers in our strategic markets. We also conducted several comparative cell preservation experiments with CryoStor against other freeze media and were very impressed by the performance of CryoStor in improving post-thaw cell viability and recovery. We feel that the robust regulatory and quality footprint of serum-free and protein-free CryoStor and HypoThermosol will increasingly be valued by researchers and clinicians around the world."

About BioLife Solutions

BioLife Solutions develops, manufactures, and markets patented hypothermic storage/transport and cryopreservation media products for cells, tissues, and organs. The Company's proprietary HypoThermosol(R) and CryoStor(TM) platform of biopreservation media products are marketed to academic research institutions, hospitals, and commercial companies involved in cell therapy, tissue engineering, cord blood banking, drug discovery, and toxicology testing. BioLife's GMP products are serum-free and protein-free, fully defined, and pre-formulated to reduce preservation-induced, delayed-onset cell damage and death. Comprehensive small animal intravenous safety studies have been completed on HypoThermosol and CryoStor, and both products are supported by US FDA Master Files. BioLife's enabling technology provides research and clinical organizations significantly enhanced post-preservation cell and tissue viability and function. For more information please visit www.biolifesolutions.com.

About STEMCELL Technologies

STEMCELL Technologies is a life sciences company dedicated to providing a range of products that support innovative research in hematology, immunology, cancer research, developmental biology, and many other areas of life science research. STEMCELL's specialized media and cell separation products are available for a wide range of research applications, and are complemented by a diverse array of cytokines, antibodies, and tissue culture reagents for use in research. Driven by science and enabled by close interactions with global leaders in cell biology and medicine, STEMCELL delivers over 900 products to research scientists in more than 70 countries worldwide. For more information please visit www.stemcell.com.

This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact. Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission. BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

    Media Relations:                    Investor Relations:
    Len Hall                            Matt Clawson
    Allen & Caron Inc                   Allen & Caron Inc
    (949) 474-4300                      (949) 474-4300
    len@allencaron.com                  matt@allencaron.com


'/>"/>
SOURCE BioLife Solutions, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioLife Solutions Announces Validation and Start-Up of New Internal Manufacturing Facility for Serum-Free Cell and Tissue Biopreservation Media Products
2. Rutgers University Cell and DNA Repository Adopts BioLife Solutions CryoStor(TM) as Standard Biopreservation Media
3. Improved Cryopreservation Outcomes in Potential $100B Tissue Engineering Market Enabled by BioLife Solutions CryoStor(TM)
4. BioLife Solutions Launches BioPreservation Today(R) Industry Newsletter
5. BioLife Solutions Joins Prestigious Biomedical Excellence for Safer Transfusion Collaborative
6. BioLife Solutions Completes Safety Studies on HypoThermosol(R) and CryoStor(TM)
7. BioLife Solutions Granted European Biopreservation Patent
8. BioLife Solutions Submits FDA Master File on HypoThermosol(R) Preservation and Storage Media for Cells, Tissues
9. BioLife Solutions HypoThermosol(R) Adopted by MicroIslet for Processing Pancreatic Islet Cells to Treat Diabetes
10. BioLife Solutions Credit Facility Increased to $9 Million
11. BioLife Solutions Announces FDA Master File Acceptance for CryoStor(TM) Pre-formulated Cryopreservation Media
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... , May 3, 2016 ... (Genomics, Drug Discovery, Gene Expression) Lab-on-a-chip (IVD ... (Academics Institutes, Diagnostics Centers), Fabrication Technology (Microarrays, ... MarketsandMarkets, the market is expected to reach ... 7.63 Billion in 2015, growing at a ...
(Date:5/3/2016)... ... May 03, 2016 , ... Flagship Biosciences, the leader in ... its Board of Directors. Dr. Gillett recently retired from Charles River Laboratories (CRL), ... Chief Scientific Officer. A board-certified veterinary pathologist, Dr. Gillett joined Charles River in ...
(Date:5/3/2016)... 2016  Dr. Thomas P. McHugh , an ... The Woodlands, Texas , now offers SculpSure, the ... fat cells in just 25-minutes, leaving a slimmer figure ... of Americans report feeling bothered by excess weight and ... are a growing industry. This innovative new approach to ...
(Date:5/2/2016)... Willoughby, Ohio (PRWEB) , ... May 02, 2016 ... ... website. Designed with its clients in mind, the fresh look and added functionality ... capabilities. , “Recent years have seen a dynamic shift in agriculture – from ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016 ... "Global Gait Biometrics Market 2016-2020,"  report to their ... ) , ,The global gait biometrics market ... 13.98% during the period 2016-2020. Gait ... which can be used to compute factors that ...
(Date:3/29/2016)... 29, 2016 LegacyXChange, Inc. (OTC: ... and SelectaDNA/CSI Protect are pleased to announce our successful ... a variety of writing instruments, ensuring athletes signatures against ... collectibles from athletes on LegacyXChange will be assured of ... DNA. Bill Bollander , CEO states, ...
(Date:3/18/2016)... , March 18, 2016 ... Suppliers of Biometrics, ICT, Manned & Unmanned Vehicles, Physical infrastructure ... & security companies in the border security market and the ... and Europe has led visiongain ... companies improved success. --> defence & security ...
Breaking Biology News(10 mins):